(Q34669325)

English

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

scientific article

Statements

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl (English)
Allen Lee Cohn
Radka Obermannova
Gyorgy Bodoky
Rocio Garcia-Carbonero
Tudor-Eliade Ciuleanu
David C Portnoy
Axel Grothey
Jana Prausová
Pilar Garcia-Alfonso
Kentaro Yamazaki
Philip R Clingan
Sara Lonardi
Tae Won Kim
Lorinda Simms
Shao-Chun Chang
Federico Nasroulah
RAISE Study Investigators

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit